Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

August 22, 2024 at 1:18pm BST A man with memory problems has said he has been able to “live a full life” while taking part in a trial of the drug lecanemab, as his symptoms have “plateaued ...

Half were given intravenous Lecanemab fortnightly, the other half being given placebo. Before treatment, and 18 months later, participants completed measures of cognitive function and β-amyloid ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers found that patients who were given the drug lecanemab in the earliest days of ...

Excitement over lecanemab was followed in 2023 by news of even better results for a similar drug - Eli Lilly's donanemab - after its Phase Three clinical trial found that it slowed cognitive ...